4//SEC Filing
Abrahmsen Lars B. 4
Accession 0001104659-21-118360
CIK 0001781983other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 5:00 PM ET
Size
9.0 KB
Accession
0001104659-21-118360
Insider Transaction Report
Form 4
Abrahmsen Lars B.
SVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2021-09-20$4.97/sh−25,000$124,250→ 19,000 total - Exercise/Conversion
Common Stock
2021-09-20$0.92/sh+25,000$23,000→ 44,000 total - Exercise/Conversion
Stock Option (right to Buy)
2021-09-20−25,000→ 80,587 totalExercise: $0.92Exp: 2026-09-14→ Common Stock (25,000 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $5.57 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option was granted on September 14, 2016 and is fully exercisable.
Documents
Issuer
Aprea Therapeutics, Inc.
CIK 0001781983
Entity typeother
Related Parties
1- filerCIK 0001789039
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 5:00 PM ET
- Size
- 9.0 KB